Clinical Evaluation of LeGoo™ Internal Vessel Occluder Versus Traditional Vessel Loops

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by Pluromed, Inc..
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Pluromed, Inc.
ClinicalTrials.gov Identifier:
NCT00985634
First received: September 24, 2009
Last updated: September 25, 2009
Last verified: September 2009
  Purpose

The primary purpose of this study is to demonstrate the clinical safety and efficacy of LeGoo™ in comparison to a standard vessel occlusion method (i.e. vessel loops). Although LeGoo™ is suitable for use in any vascular surgery where temporary vessel occlusion is desired, this study specifically focuses on the use of LeGoo™ in off-pump coronary bypass (OPCAB), as a most sensitive model of adverse changes that may occur at any vascular site.


Condition Intervention
Off Pump Coronary Artery Bypass Surgery
Device: LeGoo
Device: Control

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Randomized Clinical Evaluation of LeGoo™ Internal Vessel Occluder Vs Traditional Vessel Loops

Resource links provided by NLM:


Further study details as provided by Pluromed, Inc.:

Primary Outcome Measures:
  • The primary research hypothesis is that surgeons will obtain a bloodless surgical field and achieve satisfactory hemostasis in a larger proportion of anastomoses using LeGoo™ than using a conventional temporary hemostasis technique. [ Time Frame: in operating room ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Total duration of the anastomosis, blood loss during the surgery, Time required to occlude the vessel, the number of units of blood transfused during hospitalization. [ Time Frame: in operating room (day of surgery) ] [ Designated as safety issue: No ]
  • Safety will be measured by comparing a composite of four serious adverse events experienced by the treated and control groups: death, graft occlusion, myocardial damage, and low post procedure cardiac output. [ Time Frame: one month post op ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 110
Study Start Date: September 2008
Estimated Study Completion Date: March 2010
Estimated Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LeGoo
Subjects in this arm, which is assigned at random, will receive the study device.
Device: LeGoo
LeGoo internal vessel occluder. Usage (dose) as required and determined by surgeon.
Active Comparator: Control
Subjects in this arm will not receive the study device, but receive the standard of care for vessel occlusion (vessel loops.)
Device: Control
Vessel loops

Detailed Description:

The purpose of this study is to evaluate the clinical efficacy of LeGoo™ as compared to a traditional vessel loop. LeGoo is a device that is intended to be used during surgical procedures to temporarily occlude blood vessels while forming an anastomosis. LeGoo™ will be evaluated in subjects undergoing off-pump coronary artery by-pass (OPCAB) surgery. This is a prospective, randomized trial with a 30-day follow-up period. Half of the eligible patients will be randomized to the experimental group (LeGoo™); and the other half to the control group (standard vessel loops).

LeGoo™ is polymer-based device which is comprised of a non-toxic and biocompatible gel that exists as a liquid at low temperatures and rapidly transitions to a solid at body temperature, forming a plug that can occlude blood vessels. LeGoo™ is injected into a blood vessel that is intended to be occluded, where it stays in a "plug" form for several minutes allowing the surgeon to work in a bloodless field. The gel dissolves with time (spontaneously) or can be reversed back to liquid instantly by cooling the site with ice or irrigating with cold saline. Once dissolved below a minimum concentration, the polymer can never re-solidify.

The primary research hypothesis is that surgeons will obtain a bloodless surgical field and achieve satisfactory hemostasis in a larger proportion of anastomoses using LeGoo™ than using a conventional temporary hemostasis technique.

Satisfactory hemostasis is defined by the surgeon who will quantitate his/her observation about the quality of the surgical field using the following scoring system:

  1. - Excellent hemostasis (no bleeding)
  2. - Minimal bleeding (bleeding does not interfere with suturing)
  3. - Modest bleeding (required intermittent use of another device to control bleeding at the site of the anastomosis)
  4. - Copious bleeding (required continuous use of another device)

"Excellent hemostasis" and "minimal bleeding" are considered "satisfactory hemostasis." Satisfactory hemostasis will constitute a treatment success for the purpose of evaluating the primary efficacy of LeGoo. The primary endpoint is the proportion of anastomoses in which satisfactory hemostasis is achieved.

  Eligibility

Ages Eligible for Study:   18 Years to 79 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects undergoing elective off pump coronary artery bypass (OPCAB) surgery where the surgeon prospectively plans to use a vascular occlusion device.
  2. >70% proximal stenosis of at least one target coronary artery, other than left main
  3. Age: between the ages 18 -79 years
  4. Gender: male and female
  5. Subject is willing and able to participate in a clinical research study and provides informed consent.
  6. Subject is able and willing to participate in required follow-up procedures.

Exclusion Criteria:

  1. Previous cardiac surgery.
  2. Left ventricular dysfunction (EF <40%)
  3. >50% of left main coronary artery stenosis
  4. Subjects with a logistic EuroScore equal to or greater than 10% as calculated by the euroscore.org calculator
  5. Emergent Surgery: Subjects undergoing surgery before the start of the next working day following catheterization
  6. Creatinine > 200 µmol/L
  7. Bilirubin > 21 µmol/L
  8. Subjects with chronic pulmonary disease [ FEV1 < 45% ]
  9. Any subject who is deemed by the investigator, for any reason, not suitable or able to participate in a clinical research study.
  10. Pregnant women. Women of childbearing age will require a pregnancy test within 10 days of the operation and will be excluded if the result is positive.
  11. Women who are lactating.
  12. Subjects who have undergone other investigational therapy within 30 days prior to the operation or who are scheduled to receive investigational therapy within six months of the operation.
  13. Subjects suspected to have one intra-myocardial artery among the coronary arteries to be bypassed during that surgery.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00985634

Contacts
Contact: James A Wilkie, BS 781 932 0574 jwilkie@pluromed.com
Contact: Jean-Marie Vogel, BS 781 932 0574 jvogel@pluromed.com

Locations
Germany
Klinik fur Herzchirurgie Herzzentrum Leipzig Recruiting
Leipzig, Germany
Contact: Ardawan Rastan, MD    49 341 865-1421    jwilkie@pluromed.com   
Principal Investigator: Ardawan Rastan, MD         
Sponsors and Collaborators
Pluromed, Inc.
  More Information

No publications provided by Pluromed, Inc.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: James Wilkie / Vice President Operations, Pluromed, Inc.
ClinicalTrials.gov Identifier: NCT00985634     History of Changes
Other Study ID Numbers: LeGoo EURO rev D
Study First Received: September 24, 2009
Last Updated: September 25, 2009
Health Authority: Germany: German Institute of Medical Documentation and Information
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Pluromed, Inc.:
off pump bypass OPCAB
OPCAB

ClinicalTrials.gov processed this record on October 23, 2014